Combining pioneering iPSC technology and patented live cell bioimaging, LumiSTAR is opening up exciting new possibilities in the treatment of various diseases and the development of innovative new dru ...

These positive early-stage clinical results provide promising evidence supporting the continued development of XellSmart's XS411 for Parkinson's disease patients. Pioneering Achievements in ...

These milestones position XellSmart as a global leader in advancing innovative iPSC-derived regenerative cell therapies for CNS diseases, including Parkinson's disease and ALS. Dr. Michael Lee ...

Xellsmart Biopharmaceutical (Suzhou) Co. Ltd. has announced IND clearances by the FDA for its XS-411 and XS-228 cell therapies, for Parkinson’s disease and amyotrophic lateral sclerosis (ALS), ...

These positive early-stage clinical results provide promising evidence supporting the continued development of XellSmart's XS411 for Parkinson's disease patients. XellSmart has developed XS228, the ...

This study was officially approved by China's National Health Commission, making XellSmart the first to complete an iPSC-derived cell therapy for Parkinson's disease in China. In the clinical ...

for its universal allogeneic off-the-shelf iPS-derived dopaminergic neural progenitor cell therapy for the treatment of Parkinson's disease ... clinical-grade iPSC-derived cell drug development ...